Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer

The recent introduction of immune checkpoint inhibitor therapy has significantly improved outcomes for patients with colorectal cancer (CRC). The most pronounced clinical benefits were observed in patients with immunogenic microsatellite instable (MSI)/deficient MMR (dMMR) tumors. However, emerging...

Full description

Bibliographic Details
Published in:	OncoImmunology
Main Authors:	Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren-Burström, Bethany van Guelpen, Agnes Ling, Ingrid Ljuslinder, Richard Palmqvist
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	BRAF colorectal cancer immune checkpoints immunotherapy KRAS
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2546406

Similar Items

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
by: Yuki Nagakubo, et al.
Published: (2019-11-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients
by: Alper TOPAL, et al.
Published: (2025-08-01)

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020-06-01)

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?
by: Markus K. Diener, et al.
Published: (2021-07-01)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
by: Anna Koumarianou, et al.
Published: (2023-04-01)

Radiomics‐Based CT Prediction of KRAS/NRAS/BRAF Mutation Status in Colorectal Cancer: A Multicenter Study
by: Yinrui Yang, et al.
Published: (2025-09-01)

Clinicopathological Characteristics of Colorectal Cancer Patients with Different Mismatch Repair Statuses and Their Correlation with KRAS/NRAS/BRAF Gene Mutations
by: Jinchuan YU, et al.
Published: (2024-11-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease
by: Peter J. Belmont, et al.
Published: (2014-06-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

Molecular mechanisms of resistance and new therapeutic approaches in the treatment of colorectal cancer - a review of the literature
by: Maksymilian Janeczek, et al.
Published: (2024-10-01)

Frequency of KRAS and BRAF mutations in colorectal carcinoma and their association with clinical-pathological characteristics in a tertiary hospital in Kenya
by: Samuel Gakinya, et al.
Published: (2024-09-01)

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
by: E. E. Pisareva, et al.
Published: (2016-07-01)

Site‐Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer
by: Fumihiro Yoshimura, et al.
Published: (2025-07-01)

Synchronous Colorectal Cancer: Improving Accuracy of Detection and Analyzing Molecular Heterogeneity—The Main Keys for Optimal Approach
by: Patricia Simu, et al.
Published: (2021-02-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
by: Meryem Jafari, et al.
Published: (2022-11-01)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
by: Ulivi Paola, et al.
Published: (2012-05-01)

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO
by: V. P. Shubin, et al.
Published: (2020-10-01)

Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers
by: Zhao Liu, et al.
Published: (2025-02-01)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
by: Zeng J, et al.
Published: (2023-09-01)

A compilation of 13 patients with metastatic colorectal cancer and concomitant BRAF and RAS family mutations
by: Jigisha Srivastav, et al.
Published: (2025-08-01)

MOLECULAR MARKERS OF SENSITIVITY AND RESISTANCE OF COLORECTAL CANCER TO ANTI-EGFR T
by: A. O. Ivantsov, et al.
Published: (2016-04-01)

Plasma miRNA can detect colorectal cancer, but how early?
by: Maria L. Wikberg, et al.
Published: (2018-05-01)

Using tumor habitat-derived radiomic analysis during pretreatment 18F-FDG PET for predicting KRAS/NRAS/BRAF mutations in colorectal cancer
by: Hongyue Zhao, et al.
Published: (2024-02-01)

Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
by: Ahmad Machmouchi, et al.
Published: (2023-02-01)

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
by: Jie Zhong, et al.
Published: (2023-06-01)

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review
by: Michal Eid, et al.
Published: (2022-12-01)

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
by: Anne Hansen Ree, et al.
Published: (2024-12-01)

To Correlate the Expression of KRAS and BRAF V600e with Histological Grades and Variants in Tissue Samples of Colorectal Carcinoma
by: Hina Wasti, et al.
Published: (2023-04-01)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
by: Snehangshu Kundu, et al.
Published: (2021-07-01)

Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
by: Michael G. White, et al.
Published: (2025-05-01)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
by: XuSha Zhou, et al.
Published: (2021-09-01)

Association of <i>KRAS</i> G12C Status with Age at Onset of Metastatic Colorectal Cancer
by: Marcelo Sunagua Aruquipa, et al.
Published: (2024-02-01)

Navigating beyond the surface - prognostic significance of KRAS, NRAS, BRAF, PIK3CA, and TP53 mutations examined by exons
by: Vlad Adrian Afrăsânie, et al.
Published: (2025-06-01)

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition
by: Isabel Heidrich, et al.
Published: (2025-07-01)

Single-Cell Analysis of Circulating Tumor Cells from Patients with Colorectal Cancer Captured with a Dielectrophoresis-Based Micropore System
by: Masatoshi Nomura, et al.
Published: (2023-01-01)

Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea
by: Yu-Seon Shim, et al.
Published: (2025-10-01)